title: Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis.
abstract: Glucocorticoids (GC) are widely used to treat systemic sclerosis (SSc). The lack of efficacy data and patient/physician concerns may prompt therapy discontinuation. The aim of this study is to identify factors hampering GC discontinuation in patients with stable disease on oral GC for longer than 12 months. Consecutive patients fulfilling the 2013 ACR/EULAR criteria for SSc and with stable disease were prescribed a slow tapering GC regimen to achieve discontinuation. At study entry and 6 months later (T6), patients were assessed for disease activity and severity. Moreover, the Short-Form-36; the Health Assessment Questionnaire Disability Index (HAQ-DI); and visual analog scales for fatigue, pain, and general health were completed. Reasons for stopping the discontinuation regimen were recorded. Forty-eight patients (46 females, 9 diffuse SSc), with a mean ± SD age of 56±14 years and a median disease duration of 10 years (range 2-22), were enrolled. The median daily GC dose was 5 mg (range 5-10; all patients treated with prednisone). At T6, 33 (68.7 %) patients had discontinued GC. The remaining 15 patients could not discontinue GC because of arthralgia in eight, arthritis in two, puffy fingers in two, increased creatine-kinase in two, and bursitis in one patient. At multiple logistic analysis, a higher baseline HAQ-DI was the only independent factor associated with GC need (OR 2.98, 95 % CI 1.20-7.41; p = 0.01). About one third of SSc patients did not achieve a GC-free regimen. Disability as assessed by HAQ-DI was the leading factor hindering GC discontinuation. A low HAQ-DI score can identify candidates for GC discontinuation.
authors.affiliation: Department of Clinical and Experimental Medicine, Rheumatology Section, Second University of Naples, II Policlinico, Via Pansini 5, 80131, Naples, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Iudici
authors.affiliation: Department of Clinical and Experimental Medicine, Rheumatology Section, Second University of Naples, II Policlinico, Via Pansini 5, 80131, Naples, Italy.
authors.forename: Serena
authors.initials: S
authors.lastname: Vettori
authors.affiliation: Department of Clinical and Experimental Medicine, Rheumatology Section, Second University of Naples, II Policlinico, Via Pansini 5, 80131, Naples, Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: Russo
authors.affiliation: Department of Clinical and Experimental Medicine, Rheumatology Section, Second University of Naples, II Policlinico, Via Pansini 5, 80131, Naples, Italy.
authors.forename: Veronica
authors.initials: V
authors.lastname: Giacco
authors.affiliation: Department of Clinical and Experimental Medicine, Rheumatology Section, Second University of Naples, II Policlinico, Via Pansini 5, 80131, Naples, Italy.
authors.forename: Domenico
authors.initials: D
authors.lastname: Capocotta
authors.affiliation: Department of Clinical and Experimental Medicine, Rheumatology Section, Second University of Naples, II Policlinico, Via Pansini 5, 80131, Naples, Italy. gabriele.valentini@unina2.it.
authors.forename: Gabriele
authors.initials: G
authors.lastname: Valentini
mesh_terms: D000328:Adult; D000368:Aged; D004185:Disability Evaluation; D005221:Fatigue; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006305:Health Status Indicators; D006801:Humans; D007558:Italy; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010146:Pain; D010147:Pain Measurement; D011241:Prednisone / Q000008:administration & dosage*; D011788:Quality of Life; D012372:ROC Curve; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D012720:Severity of Illness Index; D016903:Drug Monitoring
chemical_list: D005938:Glucocorticoids; D011241:Prednisone
keywords: Discontinuation; Glucocorticoids; Systemic sclerosis